137 related articles for article (PubMed ID: 24463915)
1. The relationship between low-density lipoprotein cholesterol levels and the incidence of cardiovascular disease in high-risk patients treated with pravastatin: main results of the APPROACH-J study.
Daida H; Teramoto T; Kitagawa Y; Matsushita Y; Sugihara M
Int Heart J; 2014; 55(1):39-47. PubMed ID: 24463915
[TBL] [Abstract][Full Text] [Related]
2. APPROACH-J study: design, rationale, and baseline data of the affirmation primary prevention with pravastatin in reduction of occlusive atherosclerotic complications in hypercholesterolemia--Japan study.
Teramoto T; Kitagawa Y; Daida H;
J Atheroscler Thromb; 2011; 18(12):1054-61. PubMed ID: 21921414
[TBL] [Abstract][Full Text] [Related]
3. Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese.
Teramoto T; Nakaya N; Yokoyama S; Ohashi Y; Mizuno K; Nakamura H;
J Atheroscler Thromb; 2010 Aug; 17(8):879-87. PubMed ID: 20543522
[TBL] [Abstract][Full Text] [Related]
4. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of LDL-C-related parameters to predict cardiovascular risk and effect of pravastatin in mild-to-moderate hypercholesterolemia.
Mizuno K; Nakaya N; Teramoto T; Yokoyama S; Ohashi Y; Ueki A; Takahashi S; Kubota Y; Nakamura H
J Atheroscler Thromb; 2012; 19(2):176-85. PubMed ID: 22129522
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial.
Uchiyama S; Nakaya N; Mizuno K; Ohashi Y; Tajima N; Kushiro T; Teramoto T; Nakamura H;
J Neurol Sci; 2009 Sep; 284(1-2):72-6. PubMed ID: 19423132
[TBL] [Abstract][Full Text] [Related]
7. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
[TBL] [Abstract][Full Text] [Related]
8. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
[TBL] [Abstract][Full Text] [Related]
9. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
Strutt K; Caplan R; Hutchison H; Dane A; Blasetto J
Circ J; 2004 Feb; 68(2):107-13. PubMed ID: 14745143
[TBL] [Abstract][Full Text] [Related]
10. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
[TBL] [Abstract][Full Text] [Related]
11. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin.
Nakamura H;
Atheroscler Suppl; 2007 Aug; 8(2):13-7. PubMed ID: 17586102
[TBL] [Abstract][Full Text] [Related]
12. Effects of pravastatin on exercise electrocardiography test performance and cardiovascular mortality and morbidity in patients with hypercholesterolemia: Lipid Intervention Study in Kyoto.
Sasaki S; Nakagawa M; Nakata T; Azuma A; Sawada S; Takeda K; Asayama J;
Circ J; 2002 Jan; 66(1):47-52. PubMed ID: 11999665
[TBL] [Abstract][Full Text] [Related]
13. Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.
Lahoz C; Peña R; Mostaza JM; Laguna F; García-Iglesias MF; Taboada M; Pintó X
Metabolism; 2005 Jun; 54(6):741-7. PubMed ID: 15931608
[TBL] [Abstract][Full Text] [Related]
14. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
15. Does Lowering Low-Density Lipoprotein Cholesterol With Statin Restore Low Risk in Middle-Aged Adults? Analysis of the Observational MESA Study.
Liu K; Wilkins JT; Colangelo LA; Lloyd-Jones DM
J Am Heart Assoc; 2021 Jun; 10(11):e019695. PubMed ID: 33998284
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1,030 hypercholesterolemic patients. The Cerivastatin Study Group.
Dujovne CA; Knopp R; Kwiterovich P; Hunninghake D; McBride TA; Poland M
Mayo Clin Proc; 2000 Nov; 75(11):1124-32. PubMed ID: 11075741
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
[TBL] [Abstract][Full Text] [Related]
19. Importance of high-density lipoprotein cholesterol control during pravastatin treatment in hypercholesterolemic Japanese with type 2 diabetes mellitus: a post hoc analysis of MEGA study.
Nishimura R; Sone H; Nakagami T; Tajima N
Diabetes Res Clin Pract; 2013 May; 100(2):e31-3. PubMed ID: 23522341
[TBL] [Abstract][Full Text] [Related]
20. Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan.
Ho LT; Yin WH; Chuang SY; Tseng WK; Wu YW; Hsieh IC; Lin TH; Li YH; Huang LC; Wang KY; Ueng KC; Fang CC; Pan WH; Yeh HI; Wu CC; Chen JW;
PLoS One; 2015; 10(3):e0116513. PubMed ID: 25756522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
